BiolineRX Ltd. (TASE:BLRX) today announced success in the Phase I/II clinical trial of BL-5010 for the non-surgical removal of Seborrheic Keratosis, or warts. The keratoses were removed in 96.7% of the patients within 30 days of a single application of the drug.
The drug was found to be safe and no prolonged or irreversible clinical side effects were observed in the area of the treatment.
The trial included 60 patients in Germany and the Netherlands. The study's primary endpoints were to test the safety and efficacy of the drug for the removal of keratoses, noncancerous benign skin growths, as well as to evaluate the cosmetic results of the treatment.
The trial also showed BL-5010's effectiveness in preserving the keratosis for a histology.
BiolineRX CEO Dr. Kinneret Savitzky said, "We are reviewing our next regulatory, clinical, and business steps."
BiolineRX's share price rose 5% in morning trading to NIS 3.22, giving a market cap of NIS 382 million.
Published by Globes [online], Israel business news - www.globes-online.com - on December 28, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010